Use of an antibody against the matrix metalloproteinase-generated aggrecan neoepitope FVDIPEN-COOH to assess the effects of stromelysin in a rabbit model of cartilage degradation.
OBJECTIVE
To define the stromelysin cleavage site in the interglobular domain of rabbit aggrecan, and to determine whether the stromelysin-generated neoepitope can be used as a marker of matrix metalloproteinase (MMP) activity in vivo.


METHODS
The carboxy-terminus sequence of the stromelysin-generated hyaluronic acid-binding region (HABR) of rabbit aggrecan was determined by reverse transcription-polymerase chain reaction complementary DNA cloning and DNA sequence analysis, followed by purification and mass spectral protein sequence analysis of the HABR fragment. Active stromelysin was injected into the stifle joints of rabbits, and a stromelysin-generated aggrecan neoepitope was analyzed by Western blotting and localized in situ by indirect immunofluorescence. Proteoglycan fragments in joint fluids were quantified by a dimethylmethylene blue dye-binding assay.


RESULTS
Stromelysin cleavage of rabbit aggrecan generated a 55-kd HABR fragment that terminated in the sequence FMDIPEN: An anti-FVDIPEN antibody recognized the FMDIPEN neoepitope in situ in cartilage from stromelysin-injected joints. The appearance of the FMDIPEN neoepitope corresponded to the release of cartilage proteoglycan fragments into the joint fluid, and could be inhibited by pretreatment of the rabbits with a synthetic stromelysin inhibitor.


CONCLUSIONS
These results indicate that the anti-FVDIPEN antibody can be used to assess the role of MMPs in cartilage degradation in vivo.
Bayne
E K
EK
Merck Research Laboratories, Rahway, NJ 07065, USA.
MacNaul
K L
KL
Donatelli
S A
SA
Christen
A
A
Griffin
P R
PR
Hoerrner
L A
LA
Calaycay
J R
JR
Ayala
J M
JM
Chapman
K
K
Hagmann
W
W
D053674:Aggrecans; D000595:Amino Acid Sequence; D000818:Animals; D000906:Antibodies; D001483:Base Sequence; D002358:Cartilage, Articular / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism*; D000939:Epitopes / Q000737:chemistry* / Q000187:drug effects / Q000378:metabolism; D016326:Extracellular Matrix Proteins; D007270:Injections, Intra-Articular; D037181:Lectins, C-Type; D019278:Matrix Metalloproteinase 3; D008666:Metalloendopeptidases / Q000008:administration & dosage / Q000494:pharmacology*; D008969:Molecular Sequence Data; D011509:Proteoglycans / Q000032:analysis / Q000737:chemistry* / Q000187:drug effects / Q000378:metabolism; D011817:Rabbits; D013582:Synovial Fluid / Q000737:chemistry / Q000187:drug effects
D053674:Aggrecans; D000906:Antibodies; D000939:Epitopes; D016326:Extracellular Matrix Proteins; D037181:Lectins, C-Type; D011509:Proteoglycans; D008666:Metalloendopeptidases; D019278:Matrix Metalloproteinase 3